C Aghajanian

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Carol Aghajanian
    The Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Gynecol Oncol 115:215-20. 2009
  2. doi request reprint Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer
    Carol Aghajanian
    Memorial Sloan Kettering Cancer Center, Gynecologic Medical Oncology Service, 300 East 66th Street, New York, NY 10065, USA Weill Cornell Medical College, 445 East 69th Street, New York, NY 10021, USA Electronic address
    Gynecol Oncol 133:105-10. 2014
  3. pmc Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival
    Sewit Teckie
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Radiat Oncol 8:36. 2013
  4. doi request reprint Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study
    Carol Aghajanian
    Dept of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    Gynecol Oncol 126:424-7. 2012
  5. pmc OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Carol Aghajanian
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    J Clin Oncol 30:2039-45. 2012
  6. ncbi request reprint A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
  7. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
  8. ncbi request reprint Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
    C Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:5943-9. 2005
  9. pmc Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
    Carol Aghajanian
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:2259-65. 2011
  10. ncbi request reprint A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer
    A L Leiser
    Division of Solid Tumor Oncology, Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Gynecol Cancer 17:379-86. 2007

Detail Information

Publications63

  1. doi request reprint A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study
    Carol Aghajanian
    The Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    Gynecol Oncol 115:215-20. 2009
    ..To determine the activity and pharmacodynamics (PD) of bortezomib in platinum-sensitive epithelial ovarian or primary peritoneal cancer (EOC/PPC)...
  2. doi request reprint Independent radiologic review: Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer
    Carol Aghajanian
    Memorial Sloan Kettering Cancer Center, Gynecologic Medical Oncology Service, 300 East 66th Street, New York, NY 10065, USA Weill Cornell Medical College, 445 East 69th Street, New York, NY 10021, USA Electronic address
    Gynecol Oncol 133:105-10. 2014
    ..To evaluate the reliability of assessment of progression and objective response per RECIST, radiologic and clinical data were assessed by an independent review committee (IRC)...
  3. pmc Radiation therapy for epithelial ovarian cancer brain metastases: clinical outcomes and predictors of survival
    Sewit Teckie
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Radiat Oncol 8:36. 2013
    ..Brain metastases (BM) and leptomeningeal disease (LMD) are uncommon in epithelial ovarian cancer (EOC). We investigate the outcomes of modern radiation therapy (RT) as a primary treatment modality in patients with EOC BM and LMD...
  4. doi request reprint Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study
    Carol Aghajanian
    Dept of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    Gynecol Oncol 126:424-7. 2012
    ..To estimate the activity and tolerability of iniparib plus paclitaxel and carboplatin as initial therapy of uterine carcinosarcoma...
  5. pmc OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    Carol Aghajanian
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA
    J Clin Oncol 30:2039-45. 2012
    ....
  6. ncbi request reprint A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies
    Carol Aghajanian
    The Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:2505-11. 2002
    ..v. bolus for 2 weeks, followed by a 1-week recovery period in patients with advanced solid tumor malignancies...
  7. ncbi request reprint Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas
    Carol Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:1082-8. 2007
    ..Dosing schedules of 40 mg/m2 and 50 mg/m2 over 3 hours were also evaluated...
  8. ncbi request reprint Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer
    C Aghajanian
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:5943-9. 2005
    ..To determine the maximum-tolerated dose, pharmacodynamics, and safety of the combination of bortezomib and carboplatin in recurrent ovarian cancer...
  9. pmc Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study
    Carol Aghajanian
    Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 29:2259-65. 2011
    ..We conducted a phase II trial to assess the activity and tolerability of single-agent bevacizumab in recurrent or persistent endometrial cancer (EMC)...
  10. ncbi request reprint A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer
    A L Leiser
    Division of Solid Tumor Oncology, Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Gynecol Cancer 17:379-86. 2007
    ....
  11. ncbi request reprint Early CA-125 fluctuations in patients with recurrent ovarian cancer receiving chemotherapy
    P Sabbatini
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Int J Gynecol Cancer 17:589-94. 2007
    ..Discontinuation of therapy solely on the basis of early CA-125 increase (precycle 3), particularly with liposomal doxorubicin chemotherapy, may exclude some patients who will benefit from continued therapy...
  12. ncbi request reprint A phase 2 trial of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission
    M Juretzka
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur J Gynaecol Oncol 29:568-72. 2008
    ..To determine the effect of imatinib on progression-free survival in patients with epithelial ovarian cancer in second or greater complete clinical remission (CCR)...
  13. ncbi request reprint New agents for the treatment of ovarian cancer: the next generation
    J Dupont
    Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Gynecol Cancer 15:252-7. 2005
    ..The opportunities to change the treatment of ovarian cancer will require creative clinical trial design but the next decade promises to be filled the therapeutic advances for patients with ovarian cancer...
  14. ncbi request reprint Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer
    F C Maluf
    Developmental Chemotherapy Service and Gynecologic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Gynecol Cancer 16:1165-71. 2006
    ..3%. We conclude that the combination of cisplatin and TPZ was reasonably well tolerated in patients with recurrent or advanced cervical cancer. Further evaluation of this drug combination may be warranted...
  15. doi request reprint Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy
    O Zivanovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 112:590-3. 2009
    ..To analyze progression-free (PFS) and overall survival (OS) in patients with small cell neuroendocrine carcinoma of the cervix (SCNEC), and to determine whether platinum-based combination chemotherapy is beneficial for this population...
  16. ncbi request reprint Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study
    M A Sovak
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Int J Gynecol Cancer 17:197-203. 2007
    ..3 months (95% CI, 4.6-7.4), with a median overall survival of 13.2 months (95% CI, 11.7-18.2). We conclude that TC is an active and tolerable regimen in the treatment of patients with advanced or recurrent endometrial cancer...
  17. ncbi request reprint Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?
    J Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Gynecol Cancer 16:68-73. 2006
    ..28 months) and TD (17.75 months) (P= NS). Platinum sensitivity did not affect median OS based on sequence. Based on duration, toxicity, and OS there is no advantage of one sequence of D and T when treating patients with recurrent EOC...
  18. ncbi request reprint Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
    C Aghajanian
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 16:1852-60. 1998
    ....
  19. ncbi request reprint The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients
    M L Hensley
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Gynecol Oncol 82:464-9. 2001
    ....
  20. ncbi request reprint Endometrial stromal sarcoma: objective response to letrozole
    F C Maluf
    The Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Gynecol Oncol 82:384-8. 2001
    ..5 mg with partial response for a duration of 9 months. CONCLUSION: Letrozole at a daily dose of 2.5 mg may be effective in low-grade endometrial stromal sarcoma with positive estrogen receptors...
  21. doi request reprint Risk factors for recurrence of ovarian borderline tumors
    K K Shih
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 120:480-4. 2011
    ..The objective of this study was to identify clinicopathologic features that are associated with an increased risk of recurrence for borderline ovarian tumors (BOT)...
  22. pmc Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials
    Michelle L Harrison
    Department of Gynaecology, The Royal Marsden Hospital, London, UK
    Gynecol Oncol 106:469-75. 2007
    ....
  23. ncbi request reprint A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Invest New Drugs 25:335-41. 2007
    ..Attempts to increase the dose of BMS-247550 by decreasing the gemcitabine dose did not sufficiently ameliorate myelosuppression. Stable disease was observed in some patients with prior taxane exposure...
  24. ncbi request reprint Palliative surgery for bowel obstruction in recurrent ovarian cancer:an updated series
    Bhavana Pothuri
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 89:306-13. 2003
    ..We analyze a contemporary series of patients to determine if outcomes have changed in patients undergoing palliative surgery...
  25. ncbi request reprint Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy
    Mario M Leitao
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 91:123-9. 2003
    ..The objective was to determine the response rate to platinum retreatment of "platinum-resistant" ovarian cancer after intervening nonplatinum therapy...
  26. ncbi request reprint Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience
    Don S Dizon
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY New York 10021, USA
    Gynecol Oncol 91:584-90. 2003
    ..In addition, we sought to compare these results to the outcomes in women who received carboplatin and paclitaxel (C + T) at first relapse...
  27. ncbi request reprint Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer
    Monica Prasad
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 93:223-8. 2004
    ..We report overall costs and treatment outcomes associated with topotecan or gemcitabine administration in platinum- and paclitaxel-resistant EOC patients...
  28. ncbi request reprint Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series
    Fady Khoury-Collado
    Department of Obstetrics and Gynecology, Lutheran Medical Center, Brooklyn, NY 11220, USA
    Gynecol Oncol 105:823-5. 2007
    ..The prognosis of recurrent metastatic cervical cancer is extremely poor. Platinum-based palliative chemotherapy constitutes the mainstay of treatment. Cure is extremely rare...
  29. ncbi request reprint A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission
    Douglas Levine
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 110:2448-56. 2007
    ..The current study was conducted to determine the effect of goserelin and bicalutamide on progression-free survival (PFS) in patients with epithelial ovarian cancer who were in second or greater complete disease remission...
  30. ncbi request reprint Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual dis
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA or
    J Clin Oncol 25:4946-51. 2007
    ..To compare surgeons' operative assessments of residual disease (RD) to those identified on postoperative computed tomography (CT) scans in patients with advanced ovarian carcinoma reported to have undergone optimal primary cytoreduction...
  31. ncbi request reprint Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 106:381-7. 2007
    ..The objective of this study was to compare the response to platinum-taxane chemotherapy and subsequent outcomes between patients older and younger than 65 years of age with stages IIIC-IV epithelial ovarian cancer (EOC)...
  32. doi request reprint Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission
    Catherine S M Diefenbach
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:2740-8. 2008
    ..In this study, we describe the effects of vaccination with the HLA-A*0201-restricted NY-ESO-1b peptide on patients with epithelial ovarian cancer in high-risk first remission...
  33. ncbi request reprint Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial
    Martee L Hensley
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2824-31. 2002
    ..Few chemotherapy agents are active in leiomyosarcoma (LMS), particularly LMS that has progressed after doxorubicin treatment. We sought to determine the response to gemcitabine plus docetaxel among patients with LMS...
  34. ncbi request reprint Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Paul Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, New York, Franklin Square Hospital, Baltimore, MD, USA, and University of Marburg, Germany
    Clin Cancer Res 12:5503-10. 2006
    ....
  35. ncbi request reprint Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer
    Don S Dizon
    Department of Medicine, Division of Developmental Chemotherapy, and Department of Gynecologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
    J Clin Oncol 20:1238-47. 2002
    ..We sought to determine the outcomes for patients with EOC treated with carboplatin and paclitaxel at the time of first recurrence. In addition, we sought to define a new paradigm for disease transition in patients with EOC...
  36. ncbi request reprint The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 108:276-81. 2008
    ..It remains unresolved whether this is due to better chemotherapy response and/or simply "re-setting the clock," such that patients with less residual disease take longer to recur and succumb to their disease...
  37. ncbi request reprint Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy
    Don S Dizon
    Developmental Chemotherapy Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Gynecol Oncol 84:378-82. 2002
    ..One case is presented in which a heavily pretreated patient suffered a severe anaphylactic reaction, which was refractory to standard resuscitative measures and resulted in her death...
  38. ncbi request reprint Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up
    Richard R Barakat
    Gynecology Service, Department of Surgery, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:694-8. 2002
    ..To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy...
  39. ncbi request reprint Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer
    Catherine S M Diefenbach
    Gynecologic Medical Oncology, Department of Medicine, Howard 903, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 104:435-42. 2007
    ..In this study, we examined the frequency of serum elevation as well as the diagnostic and prognostic significance of this serum marker in endometrial cancer...
  40. ncbi request reprint Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature
    Tiffany A Traina
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 95:235-41. 2004
    ..We have included a review of the literature of weekly topotecan in the treatment of patients with gynecologic cancer...
  41. ncbi request reprint Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma
    Dennis S Chi
    Gynecology Service, Department of Surgery Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 106:1933-9. 2006
    ....
  42. ncbi request reprint Early detection and prognosis of ovarian cancer using serum YKL-40
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard 905, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3330-9. 2004
    ..YKL-40 is a secreted glycoprotein (chitinase family). We compared YKL-40 with two ovarian cancer serum markers, CA125 and CA15-3, for the detection of early-stage ovarian cancer...
  43. ncbi request reprint Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning
    Martee L Hensley
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 102:270-7. 2006
    ....
  44. ncbi request reprint Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors
    Jakob Dupont
    Developmental Chemotherapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 22:3366-74. 2004
    ..To determine maximum tolerated dose, pharmacokinetics (PK), and safety of Ro 31-7453, a novel, oral cell-cycle inhibitor...
  45. ncbi request reprint Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma
    Mario M Leitao
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 101:1455-62. 2004
    ..The authors also sought to assess the prognostic value of ER, PR, and AR expression in LMS...
  46. ncbi request reprint Temozolomide in uterine leiomyosarcomas
    Sibyl Anderson
    Developmental Chemotherapy, Gynecology Disease Management Team, Memorial Sloan Kettering Cancer Center, Gynecology Breast Services Academic Office, 1275 York Avenue, MRI 1027, New York, NY 10021, USA
    Gynecol Oncol 98:99-103. 2005
    ..We include a literature review of temozolomide activity in leiomyosarcoma patients...
  47. ncbi request reprint Clinical update: novel targets in gynecologic malignancies
    Carol Aghajanian
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 31:22-6; discussion 33. 2004
    ..The two trials indicate promising results for bortezomib in patients with solid tumors and patients with recurrent ovarian cancer, but further investigation is warranted...
  48. ncbi request reprint Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group
    Stephen D Williams
    Indiana University Cancer Center, 535 Barnhill Drive, Indianapolis, IN 46202, USA
    Gynecol Oncol 95:496-9. 2004
    ..This study was designed to evaluate the effect of adjuvant chemotherapy with carboplatin and etoposide in patients with completely resected stage IB-III dysgerminoma...
  49. ncbi request reprint Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Paul Sabbatini
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:4523-31. 2004
    ..To evaluate the safety and efficacy of CT-2103, a novel conjugate of paclitaxel and poly-L-glutamic acid, in heavily pretreated patients with recurrent ovarian, fallopian tube, or peritoneal cancer...
  50. ncbi request reprint Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study
    Mika A Sovak
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:451-7. 2006
    ..To determine overall survival and progression-free survival among patients with high-risk, stage III and IV endometrial cancer who receive paclitaxel and carboplatin (TC) after complete tumor resection...
  51. ncbi request reprint The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center
    Nadeem R Abu-Rustum
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 103:714-8. 2006
    ..To describe the incidence of symptomatic postoperative lower-extremity lymphedema in women treated for uterine corpus cancer, and to evaluate its relationship to regional lymph node removal and postoperative therapy...
  52. ncbi request reprint The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 94:307-11. 2004
    ..To analyze the findings and impact on the management of video-assisted thoracoscopic surgery (VATS) before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions...
  53. ncbi request reprint CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy
    Margrit M Juretzka
    Gynecology Oncology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 104:176-80. 2007
    ..A secondary objective was to assess the relationship of CA125 level to PFS...
  54. ncbi request reprint Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival
    Catherine S M Diefenbach
    Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 107:1511-9. 2006
    ..The significance of tumor overexpression of LPAAT-beta was investigated in a large number of advanced- and early-stage EOC patients...
  55. ncbi request reprint Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
    Michael S Gordon
    Arizona Cancer Center, Tuscon and Scottsdale, AZ, USA
    J Clin Oncol 24:4324-32. 2006
    ..Pertuzumab, a humanized antibody that prevents HER2 dimerization and inhibits multiple HER-mediated pathways, was studied in a phase II, multicenter trial in advanced, refractory OC...
  56. ncbi request reprint The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer
    Eric L Eisenhauer
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 103:1083-90. 2006
    ..To determine the survival impact of adding extensive upper abdominal surgical cytoreduction to standard surgical techniques for advanced ovarian cancer...
  57. ncbi request reprint The role of bevacizumab in ovarian cancer--an evolving story
    Carol Aghajanian
    Gynecol Oncol 102:131-3. 2006
  58. ncbi request reprint Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial
    Paul Sabbatini
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:2962-7. 2004
    ..p. cisplatin with i.p. gemcitabine in patients with persistent disease at second-look assessment, the toxicity of this regimen, and the time to treatment failure and overall survival...
  59. ncbi request reprint Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature
    Lisa Dos Santos
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 105:321-4. 2007
    ..The prognosis is generally poor when disease has spread beyond the ovary. We conducted this study to review our experience with this disease and describe our current treatment modality...
  60. ncbi request reprint Surgical resection of recurrent endometrial carcinoma
    Christopher S Awtrey
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 102:480-8. 2006
    ..The objective of this study was to review our experience with non-exenterative surgery for recurrent endometrial cancer...
  61. ncbi request reprint Management and outcome of healthy women with a persistently elevated beta-hCG
    Carlo Palmieri
    Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London, UK
    Gynecol Oncol 106:35-43. 2007
    ..Here we report the United Kingdom experience of patients with an elevated beta-hCG of initial uncertain cause and provide a clinical algorithm for the management of such cases...
  62. ncbi request reprint Craniotomy for central nervous system metastases in epithelial ovarian carcinoma
    Bhavana Pothuri
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 87:133-7. 2002
    ..Numerous series have reported various modalities for treatment with median survivals of 3 to 5 months, but the role of craniotomy has not been specifically addressed...
  63. ncbi request reprint En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report
    Lisa A dos Santos
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Gynecol Oncol 102:596-8. 2006
    ..However, direct extension of tumor into the lung is sometimes encountered, and successful resection of this type of implant has not been previously described in the gynecologic oncology literature...